News

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
In April, Danish drugmaker Novo Nordisk formed what was supposed to be a long-term collaboration to promote its weight-loss ...
Novo Nordisk Shares Post Worst Ever Week as Optimism Wanes
Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe’s most valuable public company again. Now, the stock ...
Stock Movers: Novo Nordisk, IAG, Campari
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Why Novo Nordisk Stock Crumbled Again Today
Kumar now believes the stock is only worthy of a hold recommendation, down from his previous assessment of buy. He also significantly lowered his price target, chopping it to 360 Danish krone ($55.49) ...
Ozempic maker Novo Nordisk has its worst day since Black Monday
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
24/7 Wall St.2d
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk: Catch That Falling Knife
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Novo Nordisk appoints new CEO Maziar Doustdar
July 29 (UPI) -- Novo Nordisk announced Tuesday that Mike Doustdar has been appointed as the company's new CEO. Doustdar ...
Novo Nordisk projects weaker sales as it battles copycat drugs
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Novo Nordisk downgraded to Hold at HSBC on guidance cut
Novo Nordisk (NVO) downgraded to Hold by HSBC amid growth concerns, GLP-1 market challenges, and revised 2025-2026 earnings ...